New trial
Phase 1b/2a Study of Mezigdomide Cereblon E3 Ligase Modulator & Elranatamab BCMA/CD3 Bispecific
- Trial ID
- NCT06988488 on ClinicalTrials.gov
- Cancer type
- Multiple Myeloma
- Location
- 17 Locations
- Published in
- New in Oncology - June 16, 2025
Celgene sponsors this multicenter, open‐label trial evaluating mezigdomide with elranatamab (plus dexamethasone) to establish the recommended dose and safety in relapsed/refractory multiple myeloma across 2nd–5th treatment lines.
More in multiple myeloma
-
Trial result · Oct 22, 2026 · NCT04184050
MK-4002 (BCMA×CD3 trispecific T-cell engager) drives 63% ORR at 12 mg in heavily pretreated RRMM -
Trial result · Oct 15, 2026 · NCT04557150
Forimtamig (GPRC5D×CD3 2:1 bispecific) posts 72% ORR at optimized SC dosing—but toxicity caps escalation in RRMM -
New trial · Oct 15, 2026 · NCT06948084
Phase 2 daratumumab plus teclistamab is compared with DPd or DKd in high-risk, second-line multiple myeloma -
Trial result · Oct 1, 2026 · NCT03301220
Daratumumab (anti-CD38) cuts progression risk in Japanese high-risk SMM vs monitoring (AQUILA) -
Trial result · Sep 24, 2026 · NCT05469893
Teclistamab (BCMAxCD3 bispecific) drives 78% CR and 92% 2-year PFS in high-risk smoldering myeloma